Additionally, we studied the expression levels of complement-inhibitory proteins such as CD55 and CD59 before and after ricolinostat treatment and observed an upregulation of CD59, an inhibitor of the terminal pathway of the complement cascade, on primary MM and MM cell lines (Supplementary Fig. 8). Here, CD55 is linked to Miyoshi myopathy.